Dynavax Technologies Corporation (DVAX) has been under a strong bear grip, hence the stock is down -24.9% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.22% in the past 1 week. The stock has risen by 0.76% in the past week indicating that the buyers are active at lower levels, but the stock is down -26.42% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 16.99% and the 50-Day Moving Average is 20.34%.The 200 Day SMA reached 35.37% Dynavax Technologies Corporation has dropped 16.26% during the last 3-month period . Year-to-Date the stock performance stands at -50.54%.
Dynavax Technologies Corporation (DVAX) : 3 Wall Street analysts covering Dynavax Technologies Corporation (DVAX) believe that the average level the stock could reach for the short term is $35.67. The maximum price target given is $45 and the minimum target for short term is around $17, hence the standard deviation is calculated at $16.17.
For the current week, the company shares have a recommendation consensus of Buy. Dynavax Technologies Corporation (NASDAQ:DVAX): The stock opened at $11.81 and touched an intraday high of $11.98 on Friday. During the day, the stock corrected to an intraday low of $11.61, however, the bulls stepped in and pushed the price higher to close in the green at $11.95 with a gain of 0.17% for the day. The total traded volume for the day was 1,191,236. The stock had closed at $11.95 in the previous trading session.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.